TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35946240
Drug: 0.5% minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% minocycline mouth rinse prescribed along with vitamin supplement and topical anesthetic gel
Study: 35946240
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic gel and vitamin supplement alone
Study: 35381095
Drug: Imeglimin (IMEG)
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Imeglimin (DB12509)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Imeglimin (IMEG) at 1000- and 1500-mg doses twice daily
Study: 33827289
Drug: Possible treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Possible treatment for children with profound autism
Study: 35181572
Drug: APT‐1011 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: APT‐1011 3 mg twice daily (BID)
Study: 35181572
Drug: APT‐1011 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: APT‐1011 3 mg at bedtime (HS)
Study: 35181572
Drug: APT‐1011 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: APT‐1011 1.5 mg BID
Study: 35181572
Drug: APT‐1011 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: APT‐1011 1.5 mg HS
Study: 35181572
Drug: APT‐1011 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: APT‐1011 3 mg BID
Study: 35181572
Drug: APT‐1011 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: APT‐1011 3 mg HS
Study: 33966331
Drug: HBVaxPro®-10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBVaxPro®-10 µg
Study: 34864978
Drug: Ultraslow thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraslow thrombolytic regimen (25 mg of rtPA infused in 25h)
Study: 34864978
Drug: Fast thrombolytic
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast thrombolytic regimen (50 mg of rtPA infused in 6h)
Study: 33107745
Drug: IV administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of cefquinome sulfate (2 mg/kg)
Study: 33107745
Drug: IM administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM administration of injectable cefquinome sulfate (2 mg/kg)
Study: 33107745
Drug: IM administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM administration of injectable cefquinome sulfate suspension (2 mg/kg)
Study: 38038626
Drug: Cervarix vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervarix vaccine
Study: 34621044
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg orally every day
Study: 33440015
Drug: I-gel® supraglottic
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel® supraglottic airway device
Study: 32266599
Drug: Vancomycin 15
Normalized name: vancomycin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 15 mg/kg every 12 h
Study: 32266599
Drug: Vancomycin 12
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 12 mg/kg every 8 h
Study: 32594832
Drug: Home-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based occupational therapy telerehabilitation via smartphone (Caspar Health e-system and mobile app)
Study: 33595142
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNT‐A) 100 IU/2 mL in each adductor magnus and each triceps surae
Study: 33595142
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% (2 mL)
Study: 33471640
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors alone
Study: 33471640
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors plus basal insulin
Study: 32213768
Drug: Na2FPO3/CaCO3 toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na2FPO3/CaCO3 toothpaste with 1,378 microg F/g of total soluble fluoride (TSF)
Study: 32213768
Drug: Aged toothpaste
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged toothpaste with 1,160 microg F/g TSF
Study: 32213768
Drug: Aged toothpaste
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged toothpaste with 900 microg F/g TSF
Study: 32213768
Drug: Aged toothpaste
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged toothpaste with 597 microg F/g TSF
Study: 34028359
Drug: Health care
Normalized name: Health Care Lancing Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health care mode exercise prescriptions
Study: 34028359
Drug: Scientific fitness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scientific fitness mode exercise prescriptions
Study: 37979959
Drug: Prednisone taper
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone taper
Study: 32990919
Drug: Peg‐IFN monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN monotherapy
Study: 34052096
Drug: SHBG-raising therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHBG-raising therapies
Study: 35766658
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention with daily multidisciplinary rounds by remote intensivists
Study: 33413462
Drug: EAA +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EAA + W (34.7 g protein, 24 g EAA)
Study: 33413462
Drug: MEAL (34.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEAL (34.7 g protein, 11.4 g EAA)
Study: 33118602
Drug: THC-rich cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC-rich cannabis oil (24.44 mg/mL of THC and 0.51 mg/mL of CBD), initial dose of one drop (∼1.22 mg of THC and 0.02 mg of CBD) a day, increased according to symptoms
Study: 36258217
Drug: TCM granules
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCM granules combined with PPI step-down therapy
Study: 36258217
Drug: TCM granules
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCM granules placebo combined with PPI step-down therapy
Study: 34793265
Drug: CJC-1134-PC (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJC-1134-PC (2 mg single dose or titrated doses of 2 + 3 and 2 + 3 + 4 mg at weekly intervals)
Study: 34793265
Drug: CJC-1134-PC (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJC-1134-PC (1, 2, 3, and 4 mg weekly doses)
Study: 32946978
Drug: First set
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First set of coated tablets
Study: 32946978
Drug: Second set
Normalized name: Second Set 42"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second set of coated tablets
Study: 32556157
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + sVIP (entecavir + peg‐IFN alfa‐2a [180 µg every week over 48 weeks] plus sequential HBV vaccination [20 µg of HBsAg on weeks 52, 56, 60, and 76])
Study: 32443306
Drug: Luofengning granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luofengning granule (LFN‐G)
Study: 32348624
Drug: Guided Biofilm
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided Biofilm therapy (GBT) with plaque disclosing agent
Study: 32348624
Drug: Control without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control without plaque disclosing agent
Study: 35551292
Drug: Dorzagliatin add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzagliatin add-on therapy to metformin (1,500 mg per day)
Study: 35551292
Drug: Placebo add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo add-on therapy to metformin (1,500 mg per day)
Study: 32713349
Drug: 3R intervention
Normalized name: (2S,3R)-(-)-Threonine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3R intervention (two facilitated group education sessions, 44 weeks of medication reminders, motivational text messages, and two coaching calls)
Study: 38505522
Drug: Abaloparatide 80
Normalized name: ABALOPARATIDE 80MCG/0.04ML PEN 1.56ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide 80 μg
Study: 35231563
Drug: Motion cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motion cohort (tibial implant taken through gentle range of motion)
Study: 32546975
Drug: Midazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.02 mg/kg)
Study: 32546975
Drug: Control (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (20 mL intravenous saline)
Study: 34492709
Drug: 6-month cycling
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month cycling aerobic exercise intervention (thrice weekly, moderate-vigorous intensity)
Study: 34492709
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise dose
Study: 35839558
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) 2400 mg daily
Study: 35583273
Drug: GSK2330811 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330811 100 mg
Study: 35583273
Drug: GSK2330811 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330811 300 mg
Study: 33408274
Drug: 3-dose schedule
Normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose schedule (0, 1, and 6 months) of 20 µg rHBV vaccine IM
Study: 33408274
Drug: 4-dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-dose schedule (0, 1, 2 and 6 months) of 20 µg rHBV vaccine IM
Study: 33408274
Drug: Accelerated 3-dose
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated 3-dose schedule (0, 1, 2 months) of 20 µg rHBV vaccine IM
Study: 32286685
Drug: Tablet-based intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based intervention with audiovisual presentation on coping strategies
Study: 33307783
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy and exercise (group I)
Study: 33307783
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy only (group III)
Study: 34732139
Drug: LPO-system-lozenge with
Normalized name: N Ice with Vitamin C Lozenge Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPO-system-lozenge with 0.083% H2O2 (B)
Study: 34732139
Drug: LPO-system-lozenge with
Normalized name: N Ice with Vitamin C Lozenge Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPO-system-lozenge with 0.04% H2O2 (C)
Study: 34732139
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge (D)
Study: 35554097
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg CU+
Study: 35554097
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg CU+
Study: 35554097
Drug: STE (1900
Approvals — FDA: no, EMA: no, PMDA: no
Description: STE (1900 mg)
Study: 32457071
Drug: Cabergoline (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (dopamine D2 receptor agonist)
Study: 33933112
Drug: Early childhood
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early childhood education machine (uniform type) in addition to routine standard treatment and nursing
Study: 33933112
Drug: Routine standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine standard treatment and nursing
Study: 36402276
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health application with relational agent
Study: 32830332
Drug: Polytherapy (Bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytherapy (Bright Light Therapy + Escitalopram Oxalate)
Study: 32830332
Drug: Monotherapy (Escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (Escitalopram Oxalate only)
Study: 32830332
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Polytherapy and Monotherapy)
Study: 32336721
Drug: Emerging new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging new therapeutic strategies using proprotein convertase subtilisin‐kexin type 9 inhibitors or antisesnse oligonucleotide technology
Study: 32336721
Drug: Conventional pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacological therapies (statin, niacin, cholesteryl ester transfer protein)
Study: 33765997
Drug: Non-suppression of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-suppression of viral load (>1000 copies/mL)
Study: 33765997
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy of ≥1 year
Study: 33765997
Drug: Self-reported better
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported better adherence to antiretroviral drugs
Study: 33605836
Drug: Cinnamon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (3 g capsules)
Study: 32726531
Drug: TY014 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY014 (2 mg/kg)
Study: 32726531
Drug: TY014 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY014 (20 mg/kg)
Study: 35777058
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 2% mepivacaine (group M)
Study: 32070396
Drug: Multi-family therapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-family therapy (MFT)
Study: 32070396
Drug: Systemic single-family
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic single-family therapy (SFT)
Study: 33112463
Drug: Topical herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical herbal solution (MTS + THS)
Study: 33229019
Drug: Life Goals
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life Goals Programme (LGP) - six weekly group sessions
Study: 32907801
Drug: Tapering TNF-inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering TNF-inhibitor first
Study: 32907801
Drug: Tapering csDMARD
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering csDMARD first
Study: 38296197
Drug: Adjunctive Reflectance
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Reflectance Confocal Microscopy (RCM)
Study: 32098536
Drug: Conventional incubator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional incubator (K‐System G‐185 Flatbed)
Study: 33942350
Drug: Postdiagnosis aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postdiagnosis aspirin use
Study: 33942350
Drug: Postdiagnosis aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postdiagnosis aspirin use (≤ 1 maximum defined daily dose)
Study: 33942350
Drug: Postdiagnosis aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postdiagnosis aspirin use (> 1 maximum defined daily dose)
Study: 32579773
Drug: Topical platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical platelet gel (PG)
Study: 32998324
Drug: Lutein (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (12 mg)
Study: 33292081
Drug: Topical refrigerant
Normalized name: Refrigerant 114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical refrigerant spray (TRS)
Study: 35367525
Drug: Trametinib (1.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (1.0, 1.5, and 2.0 mg daily for 28 days) plus whole brain radiation therapy (WBRT, 37.5 Gy/15 fractions)
Study: 36189534
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine solution
Study: 36069869
Drug: Open-source automated
Normalized name: AMYLOPECTIN, UNSPECIFIED SOURCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-source automated insulin delivery (AID) system
Study: 33346789
Drug: 25 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg/day cannabidiol (CBD25)
Study: 33346789
Drug: 50 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg/day cannabidiol (CBD50)
Study: 39661119
Drug: Atrasentan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 0.75 mg/day
Study: 32517390
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve pulsed radiofrequency (PRF) treatment
Study: 35598122
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) + Taurine (NT) (500 mg Taurine + 150 mg NAC)
Study: 35104607
Drug: Anodal high-definition
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal high-definition transcranial direct current stimulation (HD-tDCS) administered to the right inferior frontal gyrus (rIFG) for 5 consecutive days, twice a day.
Study: 35104607
Drug: Sham HD-tDCS
Normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham HD-tDCS administered to the right inferior frontal gyrus (rIFG) for 5 consecutive days, twice a day.
Study: 35458108
Drug: DGA +
Normalized name: Dextrose, Glutamine, and Arginine Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DGA + POTATO (17.5 g/day resistant starch)
Study: 35458108
Drug: DGA +
Normalized name: Dextrose, Glutamine, and Arginine Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DGA + BAGEL (0 g/day resistant starch)
Study: 34464517
Drug: BAY 1193397
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1193397 (single oral doses of 0.5-50 mg)
Study: 34464517
Drug: BAY 1193397
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1193397 (single doses of 1 and 10 mg)
Study: 34464517
Drug: BAY 1193397
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1193397 (multiple doses of 2 and 5 mg twice daily and 10 and 20 mg once daily for 9 consecutive days)
Study: 35871702
Drug: 3% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% potassium nitrate gel (UltraEZ)
Study: 35871702
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBM) with a low-level infrared laser (100 mW, spot size of 0.028 cm2, dose of 1 J per point)
Study: 35871702
Drug: 3% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% potassium nitrate gel + PBM
Study: 32075440
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IV acetaminophen and IV ketorolac
Study: 35820741
Drug: Heat therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat therapy with natural thermal mineral water (38°C)
Study: 34570798
Drug: Video of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video of Trump endorsing the vaccine
Study: 32067288
Drug: 5-hydroxytryptophan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (50 mg daily for 4 weeks)
Study: 33971278
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU bolus dose of vitamin D plus 1000 IU daily supplement for six weeks
Study: 33971278
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU daily supplement alone
Study: 34321042
Drug: Technology-supported sitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology-supported sitting balance therapy (12 sessions of 50 min over four weeks)
Study: 34878659
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks for ≤2 years)
Study: 34878659
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2 IV every week)
Study: 33915251
Drug: Nab-paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (100 mg/m2 on days 1, 8, and 15 of a 21-day cycle)
Study: 33915251
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2 on day 1)
Study: 35833913
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (clopidogrel plus aspirin)
Study: 36184258
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Atomoxetine (ATO) + 5 mg Oxybutynin (OXY)
Study: 36440985
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg orally 2 hours before surgery
Study: 36440985
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg orally
Study: 34701225
Drug: 3D Conformal
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D Conformal Radiation Therapy (3DCRT)
Study: 35429005
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive therapy (I‐CT) for 10 weeks
Study: 35964063
Drug: Family-based Improvement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based Improvement for Health Literacy (FAMILY) intervention, which includes health literacy education interventions such as project preparation, core group building, promotion within family branch, and competition between family branches.
Study: 32521976
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (ONS) 2092 kJ/day, whole protein enteral nutrition for 90 days after discharge